• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Abdominal Neoplasms

Abdominal Neoplasms - 350 Studies Found

Completed : Comparison of Hemodynamics Between Dexmedetomidine and Propofol for Sedation in Patients With Abdominal Surgery
:
  • Disorder; Mental, Sedative
  • Pain, Postoperative
  • Surgery : 2014-10-27
    :
    • Drug: Propofol Sedation

Not yet recruiting : EDMONd - Elemental Diet in Bowel Obstruction
:
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Ovarian Disease
  • : 2017-04-03
    : Dietary Supplement: Elemental 028 Extra Liquid A nutritionally complete, liquid elemental diet consistin
Completed : Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery
:
  • Malignant Gastrointestinal Neoplasm
  • Malignant Peritoneal Neoplasm

: 2015-01-29
:
  • Device: Management of Therapy Complications Fitbit Zip (portable pedometer d

Active, not recruiting : Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
:
  • Fallopian Tube
  • Primary Peritoneal Cancer
  • Solid Tumors (e.g
    : 2011-04-04
    : Drug: ABT-767 ABT-767 once or twice daily for a 28 day cycle
Completed : Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
:
  • Prostatic Neoplasm
  • Genital Neoplasms, Male
  • Neoplasms, Abdo
    : 2011-03-14
    : Drug: STI571 (Glivec®) Other Name: Glivec
Withdrawn : A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
: Ovarian, Fallopian Tube and Peritoneal Cancer
: 2014-10-27
:
  • Biological: Vaccine--‐primed, CD3/CD28--‐costimulated autologous

Completed : AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
: 2014-10-14
:
  • Drug: AZD1775 + carboplatin AZ

Completed : "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
: 2013-06-11
:
  • Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs)

Terminated : Abraxane/Bevacizumab
:
  • Ovarian Cancer
  • Peritoneal Cancer

: 2013-03-27
:
  • Drug: Abraxane Abraxane will b

Recruiting : An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
: Peritoneal Neoplasms
: 2012-09-28
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.